You are here

  • Home
  • Archive
  • Volume 66, Issue 6
  • Adalimumab alone and in combination with disease-modifying antirheumatic drugs for the treatment of rheumatoid arthritis in clinical practice: the Research in Active Rheumatoid Arthritis (ReAct) trial

Citation Tools

Article menu

Download PDFPDF

Extended reports
Adalimumab alone and in combination with disease-modifying antirheumatic drugs for the treatment of rheumatoid arthritis in clinical practice: the Research in Active Rheumatoid Arthritis (ReAct) trial
Free

Download to a citation manager

Download the citation for this article by clicking on one of the following citation managers:

Cite this article as:
Burmester GR, Mariette X, Montecucco C on behalf of the Research in Active Rheumatoid Arthritis Trial study group, et al
Adalimumab alone and in combination with disease-modifying antirheumatic drugs for the treatment of rheumatoid arthritis in clinical practice: the Research in Active Rheumatoid Arthritis (ReAct) trial
Annals of the Rheumatic Diseases 2007;66:732-739.